Presenting author



## Introduction


- Lenacapavir (LEN) is a first-in-class, multistage inhibitor of HIV-1 capsid function in clinical development that was recently approved in Canada, the European Union, and the US for use in adults with multidrug-resistant HIV-1 infection<sup>1-3</sup>
- LEN is highly potent against HIV-1 in vitro and maintains wild-type activity across HIV-1 isolates with resistance to all existing drug classes<sup>2,4</sup>
- In clinical trials, LEN has shown high levels of efficacy in people with HIV-1 who are treatment-naïve or -experienced<sup>5-7</sup>; however, a comprehensive characterization of the antiviral activity of LEN against HIV-2 is lacking
- HIV-2 is endemic in West Africa and is found in other regions with socioeconomic ties to West African countries
- HIV-2 is intrinsically resistant to many antiretroviral (ARV) drugs used for HIV-1 treatment
- High rates of multiclass drug resistance have been reported in people living with HIV-2 (PLWH2) who have received ARV therapy; many such people have few fully active treatment options<sup>8-10</sup>
- The availability of a new, HIV-2-active ARV class could provide a much-needed option for second-line or salvage therapy and potentially improve ARV therapy outcomes in PLWH2

## Objective

To study the activity of LEN against a panel of HIV-2 isolates with or without resistance to existing drug classes

## Methods

- The activity of LEN against HIV-1 and -2 isolates from ARV-naïve individuals was directly compared in 2 different assays: singlecycle infections of HeLa-CD4-CCR5-LTR-β-galactosidase (MAGIC-5A) indicator cells and multicycle infections of an immortalized T-cell line (CEM-NKR-CCR5-Luc)<sup>11</sup>
- Drug-resistant HIV-2 variants with mutations in reverse transcriptase (RT) and integrase (IN) were tested for resistance to LEN in the single-cycle assay
- Simian immunodeficiency virus of macaques (SIV<sub>mac</sub>) 251 was tested for LEN susceptibility in both single- and multicycle assays
- Sooty mangabey SIV (SIV<sub>sm</sub>) E660, SIV<sub>mac</sub> 239, and African green monkey SIV (SIV<sub>agm</sub>) sab2 were also tested in the single-cycle assay




FFU = focus-forming units; NIH HRP = National Institutes of Health HIV Research Program; PBMC = peripheral blood mononuclear cells; TCID<sub>50</sub> = 50% tissue culture infectious dose.


# **Antiviral Activity of Lenacapavir Against HIV-2 Isolates**

Robert Smith,<sup>1\*</sup> Dana Raugi,<sup>2</sup> Robbie Nixon,<sup>1</sup> Moussa Seydi,<sup>2</sup> Nicolas Margot,<sup>3</sup> Christian Callebaut,<sup>3</sup> Geoffrey S. Gottlieb<sup>1,4</sup>

<sup>1</sup>Center for Emerging and Re-Emerging Infectious Diseases, University of Washington, Seattle, WA; <sup>2</sup>Service des Maladies Infectieuses et Tropicales, CHNU de Fann, Dakar, Senega; <sup>3</sup>Gilead Sciences, Inc., Foster City, CA; <sup>4</sup>University of Washington, Seattle, WA



### Multicycle Drug Susceptibility Assays



ffer and substrate from Bright-Glo™ Luciferase Assay System (Promega Corporation, Madison, WI)

## Results

#### Susceptibility of HIV-1, HIV-2, and SIV Isolates to LEN: **Single-Cycle Assay**


Virus	Isolate	Group/Subtype	IC <sub>50</sub> , nM <sup>a</sup>	No. of Assays
HIV-1	92UG029	M/A	$0.19 \pm 0.067$	3
	NL4-3	M/B	0.15 ± 0.067	10
	89.6	M/B	$0.22 \pm 0.079$	3
	LAI	M/B	0.14 ± 0.036	3
	MJ4	M/C	0.31 ± 0.18	4
	92UG001	M/D	$0.23 \pm 0.066$	3
	94UG114.1.6	M/D	$0.20 \pm 0.064$	3
	93BR020	M/F	0.31 ± 0.15	3
	MVP5180-91	Ο	$0.19 \pm 0.080$	3
	BCF01	0	0.14 ± 0.031	3
HIV-2	ROD9	A	$2.3 \pm 0.98$	5
	ST	A	1.6 ± 0.33	3
	7924A	A	$2.2 \pm 0.85$	3
	MVP15132	A	2.8 ± 0.93	3
	60415K	A	2.7 ± 0.33	3
	CBL-20	A	2.4 ± 0.24	3
	CBL-23	A	$1.7 \pm 0.80$	3
	CDC77618	A	2.6 ± 0.40	3
	EHO	В	$2.5 \pm 0.42$	3
	CDC310072	В	$2.5 \pm 0.44$	3
	CDC310319	В	3.2 ± 0.51	3
	7312A	CRF01_AB	1.1 ± 0.10	3
SIV	sm E660	_	0.85 ± 0.11	3
	mac239 SpX	_	0.81 ± 0.37	3
	mac251	—	1.1 ± 0.077	3
	agm sab2	—	0.61 ± 0.14	3

- In the single-cycle assay, LEN inhibited HIV-1 with a mean  $IC_{50}$  of 210 pM (range 140-310 [n = 10 isolates])
- In comparison, the mean IC<sub>50</sub> for HIV-2 was 2.3 nM (range 1.1-3.2 [n = 12 isolates]), indicating an average 11-fold decrease in the activity of LEN against HIV-2 vs -1
- SIV isolates from SIV<sub>sm</sub>, as well as SIV<sub>aqm</sub> sab2, showed susceptibilities to LEN that were similar to HIV-2

#### Susceptibility of HIV-1, HIV-2, and SIV Isolates to LEN: **Multicycle Assay** Virus Isolate **Group/Subtype** IC<sub>50</sub>, nM<sup>a</sup> No. of Assays 92UG029 $0.20 \pm 0.068$ M/A Q23-17 M/A $0.12 \pm 0.038$ M/B $0.12 \pm 0.071$ NL4-3 HIV-1 M/B 0.12 ± 0.037 93BR020 M/F $0.17 \pm 0.094$ BCF01 0 $0.074 \pm 0.0051$ ROD9 3.1 ± 0.36 ST 1.3 ± 0.32 MVP15132 1.2 2.6 ± 0.87 60415K HIV-2 CDC77618 $1.2 \pm 0.018$ CDC310072 2.8 ± 1.9 CDC310319 3.4 ± 1.9 7312A $1.1 \pm 0.16$ CRF01 1.3 ± 0.57

<sup>a</sup>Multicycle infections of CEM-NKR-CCR5-Luc cells

In the multicycle assay, a comparable difference in LEN activity between HIV-1 and -2 was noted, with mean IC<sub>50</sub> values of 130 pM for HIV-1 (range 74-200 [n = 6 isolates]) and 2.1 nM for HIV-2 (range 1.1-3.4 [n = 8 isolates])




Data are from single-cycle assay; data points indicate amounts of β-galactosidase activity produced in LEN-treated cultures relative to solvent-only (if no-drug) control cultures; each point is mean of 2 cultures that were maintained in parallel; IC<sub>50</sub> and R<sup>2</sup> values were calculated using 4-factor regression model in Prism v6.0h (GraphPad Software, Boston, MA); error bars indicate standard deviations (SDs).

Activity of LEN Against Dr	ug-Resistant HIV-2 Mutants
Mutotod	Eald

Virus	Mutated Clone	Region	Mutation	Fold IC <sub>50</sub> , nMª	Difference <sup>b</sup>
HIV-2	pROD9	None	None	1.3 ± 0.23	—
HIV-2	pROD9	RT	K65R+Q151M+M184V	1.0 ± 0.015	0.79
		RT⁰	K65R+N69S+V111I+Q151M+M184V	0.96 ± 0.0053	0.73
		IN	I84V+Q91R+T97A+Y143C	1.2 ± 0.048	0.93
		IN	G140S+Q148H	1.2 ± 0.17	1
		IN	R263K	1.6 ± 0.24	1.2
		IN	231ins SREGK <sup>d</sup>	$1.2 \pm 0.48$	0.92
HIV-1	pNL4-3	None	None	0.10 ± 0.0056	0.08

14L, H228Q, I251V, L270I, and K277R; "Insertion of 5 amino acids (serine-arginine-glutamic acid-glycine-lysine) at codon 231 of IN

Presence of drug resistance mutations in HIV-2 RT or IN had no effect on LEN activity (fold-change in LEN IC<sub>50</sub>: 0.73-1.2 relative to wild-type HIV-2<sub>PODa</sub>)



observed for individual isolates of HIV-1 and -2; P values calculated via analysis of variance with Tukey's post-tes

## Conclusions

- In this study, LEN was active against HIV-2 isolates with low-nanomolar activity
- LEN potency against HIV-2 was reduced 11- to 16-fold in comparison to HIV-1 regardless of presence of drug resistance mutations in HIV-2 RT or IN
- As a result of this difference in potency, treating PLWH2 with a LEN-based regimen could require careful monitoring to assess virologic responsiveness
- These data provide information on the potential clinical utility of LEN in PLWH2 for whom treatment options are limited

References: 1. Bester S, et al. Science 2020;370:360-4; 2. Link J, et al. Nature 2020;584:614-8; 3. Paik L. Drugs 2022;82:1499-504; 4. Margot N, et al. Antimicrob Agents Chemother 2021;65:e02057-20; 5. Margot N, et al. J Antimicrob Chemother 2022;77:989-95 6. Margot N, et al. J Infect Dis 2022;226:1985-91; 7. Segal-Maurer S, et al. N Engl J Med 2022;386:1793-803; 8. Berzow D, et al. Clin Infect Dis 2021;72:503-9; 9. Gottlieb G, et al. Lancet HIV 2018;5:e390-9; 10. Visseaux B, et al. Infect Genet Evol 2016;46:233-40; Smith RA, et al J Infect Dis 2022:226:497-509 Acknowledgments: This study was funded by grants to Dr Gottlieb from the National Institute of Allergy and Infectious Diseases at

IIH (R01 AI120765), and the University of Washington Center for AIDS Research (NIH-funded program P30 AI027757). These agencies had no role in the design of the study, data collection, or interpretation of the findings. LEN was kindly provided by Gilead Sciences, Inc. Editing and production assistance were provided by BioScience Communications, New York, NY, funded by Gileac Disclosures: R Smith, D Raugi, R Nixon: nothing to disclose; M Seydi: grant funds and clinical support from Gilead, ANRS, GSK N Margot, C Callebaut: employees and shareholders of Gilead; GS Gottlieb: research grants and support from Gilead, Abbott, Alere, Bill & Melinda Gates Foundation, BMS, Cerus, Janssen, MSD, Roche, NIH, Theratechnologies/TaiMed, University of Washington, ViiV.